A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus



Status:Withdrawn
Conditions:Diabetes, Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:20 - Any
Updated:4/21/2016
Start Date:February 2015
End Date:June 2016

Use our guide to learn which trials are right for you!

A Comparison of LY2605541 Versus Insulin Glargine as Basal Insulin Treatment in Combination With Oral Anti-Hyperglycemia Medications in Insulin-Naïve Patients With Type 2 Diabetes Mellitus: An Open-Label, Randomized, 52-week Study

The main purpose of this study is to compare the efficacy and safety of a new basal insulin,
insulin peglispro, to insulin glargine in participants with type 2 diabetes mellitus (T2DM).
Both drugs will be given by an injection under the skin. Participants may continue to take
oral antihyperglycemic medication (OAM) during the study, as prescribed by their personal
physician. The study is expected to last about 12 months for each participant.


Inclusion Criteria:

- Have T2DM (per World Health Organization [WHO] Classification of Diabetes) not
treated with insulin.

- Have had diabetes for at least 1 year.

- Have been receiving at least 2 oral antihyperglycemic medications (OAMs) for at least
3 months prior to the study.

- Have hemoglobin A1c (HbA1c) of 7.0% to 11.0%, inclusive, according to central lab at
screening.

- Have body mass index (BMI) ≤40 kilogram/square meter (kg/m^2).

- This inclusion criterion applies to females of child-bearing potential (not
surgically sterilized and between menarche and 1-year postmenopausal) only: are not
breastfeeding, test negative for a serum pregnancy test, intend not to become
pregnant during study or willing to have a reliable method of birth control.

Exclusion Criteria:

- Insulin therapy: have used insulin therapy (outside of pregnancy) anytime in the past
2 years, except for short-term treatment of acute conditions, and up to a maximum of
4 continuous weeks. Insulin use of any duration during pregnancy is not considered an
exclusion criterion.

- Concomitant medications: rosiglitazone, pramlintide, glucagon-like peptide-1 (GLP-1)
receptor agonist (for example, exenatide, exenatide once weekly, or liraglutide) used
concurrently or within 3 months prior to screening.

- Local OAM restrictions: for participants on OAMs, restrictions for cardiac, renal,
hepatic diseases and maximum dose, local product regulations must apply.

- Weight loss medications: are currently taking, or have taken within the 3 months
preceding screening, prescription or over-the-counter medications to promote weight
loss.

- Severe hypoglycemia history: have had any episodes of severe hypoglycemia within 6
months prior to screening.

- Diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar nonketotic coma (HHNKC):
have had 1 or more episodes of DKA or hyperosmolar state/coma in the past 6 months.

- Cardiovascular: have cardiac disease with functional status that is New York Heart
Association Class III or IV (per New York Heart Association [NYHA] Cardiac Disease
Classification).

- Renal: have a history of renal transplantation, or are currently receiving renal
dialysis or have serum creatinine ≥2 milligram/deciliter (mg/dL) (177 micromole/liter
[mol/L]).

- Hepatic: have obvious clinical signs or symptoms of liver disease (excluding
non-alcoholic fatty liver disease [NAFLD]), acute or chronic hepatitis, non-alcoholic
steatohepatitis (NASH), or elevated liver enzyme measurements.

- Lipid-lowering medications:

- Are using niacin preparations as a lipid-lowering medication or bile acid
sequestrants within 90 days prior to screening; or,

- Are using lipid-lowering medication at a dose that has not been stable for ≥90
days prior to screening.
We found this trial at
10
sites
1709 S Rock Rd
Wichita, Kansas 67207
316-689-6629
?
mi
from
Wichita, KS
Click here to add this to my saved trials
Albuquerque, New Mexico 87102
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Birmingham, Alabama 35205
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Dayton, Ohio 45417
?
mi
from
Dayton, OH
Click here to add this to my saved trials
Hickory, North Carolina 28602
?
mi
from
Hickory, NC
Click here to add this to my saved trials
Indianapolis, Indiana 46227
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Kennewick, Washington 99336
?
mi
from
Kennewick, WA
Click here to add this to my saved trials
Saint Louis, Missouri 63110
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Wilmington, North Carolina 28401
?
mi
from
Wilmington, NC
Click here to add this to my saved trials
Zephyrhills, Florida 33542
?
mi
from
Zephyrhills, FL
Click here to add this to my saved trials